BBIO Latest Press Releases

-- August 3, 2026 --

BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET Globe Newswire 7:30 AM

-- July 22, 2026 --

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 Globe Newswire 7:30 AM

-- July 10, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- July 2, 2026 --

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM Globe Newswire 7:30 AM

-- July 1, 2026 --

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches Globe Newswire 7:30 AM

-- June 28, 2026 --

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia Globe Newswire 4:00 PM

-- June 23, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:31 PM

-- June 22, 2026 --

International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma Globe Newswire 9:05 AM

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026 Globe Newswire 7:30 AM

-- May 27, 2026 --

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 Globe Newswire 7:30 AM

-- May 12, 2026 --

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 Globe Newswire 7:30 AM

-- May 11, 2026 --

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure Globe Newswire 9:30 AM

-- May 8, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 7, 2026 --

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates Globe Newswire 4:01 PM

-- May 6, 2026 --

BridgeBio to Participate in May and June Investor Conferences Globe Newswire 4:01 PM

BEYONTTRA (acoramidis), the First Near-Complete TTR Stabilizer (=90%), Approved by ANVISA to Treat ATTR-CM in Brazil Globe Newswire 7:30 AM

-- May 5, 2026 --

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE Globe Newswire 7:30 AM

-- May 4, 2026 --

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 Globe Newswire 7:30 AM

-- April 30, 2026 --

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET Globe Newswire 7:30 AM

-- April 28, 2026 --

BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby Advocates, Morgan Freeman and Sports Business Icon Howard H. White Globe Newswire 7:30 AM

-- April 22, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- March 30, 2026 --

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 Globe Newswire 3:30 PM

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 Globe Newswire 7:30 AM

-- March 23, 2026 --

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions Globe Newswire 7:30 AM

-- March 20, 2026 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- March 11, 2026 --

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 Globe Newswire 2:00 PM

-- March 4, 2026 --

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference Globe Newswire 7:30 AM